Glenn J Hanna, Anne O'Neill, Kee-Young Shin, Kristine Wong, Vickie Y Jo, Charles T Quinn, Jennifer M Cutler, Michelle Flynn, Patrick H Lizotte, Donald J Annino, Laura A Goguen, Jason I Kass, Eleni M Rettig, Rosh K V Sethi, Jochen H Lorch, Jonathan D Schoenfeld, Danielle N Margalit, Roy B Tishler, Peter C Everett, Anupam M Desai, Megan E Cavanaugh, Cloud P Paweletz, Ann Marie Egloff, Ravindra Uppaluri, Robert I Haddad
PURPOSE: Surgery often represents the best chance for disease control in locoregionally recurrent squamous cell carcinoma of the head and neck (SCCHN). We investigated dual immune-checkpoint inhibition [anti-PD-1, nivolumab (N), and anti-KIR, lirilumab (L)] before and after salvage surgery to improve disease-free survival (DFS). PATIENTS AND METHODS: In this phase II study, patients received N (240 mg) + L (240 mg) 7 to 21 days before surgery, followed by six cycles of adjuvant N + L...
February 1, 2022: Clinical Cancer Research